CG Oncology (CGON) Share-based Compensation (2023 - 2026)

CG Oncology (CGON) has 4 years of Share-based Compensation data on file, last reported at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 25.68% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $28.0 million (up 86.21% YoY), and the FY2025 full-year result was $26.7 million, up 133.96% from the prior year.
• Share-based Compensation for Q1 2026 stood at $6.5 million, down from $7.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $7.3 million in Q3 2025 and bottomed at $177000.0 in Q2 2023.
• The 4-year median for Share-based Compensation is $2.6 million (2024), against an average of $3.5 million.
• The widest annual swing landed in 2024, when Share-based Compensation surged 1168.93%; it then rose 25.68% in 2026.
• A 4-year view of Share-based Compensation shows it stood at $778000.0 in 2023, then soared by 541.39% to $5.0 million in 2024, then jumped by 44.03% to $7.2 million in 2025, then dropped by 9.92% to $6.5 million in 2026.
• The last three Share-based Compensation figures came in at $6.5 million (Q1 2026), $7.2 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.

Peer Comparison